1Derek AW, Adrian RM, Paul R, et al. COX- 1, COX-2 and COX-3 and future treatment of chronic inflammatory disease [J]. Lancet, 2000,355(9204) :646-648.
2MacRae F, Sergio F. Cyclooxygenase-2 and atherosclerosis[J]. Curr Opin Lipidol,2002,13(5):497-504.
3Vane J, Botting RM. The future of NSAID therapy:selective COX-2 inhibitors [J]. Int J Clin Practice,2000,54(1):7-9.
4Zaid AM, Suzanne KS. Cyelooxygenase-2 and atherosclerosis: friend or foe [J] ? Neph Dial Tran,2001,16(12) :2286-2289.
5Pearson TA ,Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003,107(2) :499-511.
6Francesco C, Cesaria P, Barbara P, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-depandent plaques in instability [J]. Circulation,2001,104(4) :921-927.
7Altman R, Luciardi HL, Muntaner J, et al. Efficacy of assessment of meloxicam, a preferential COX-2 inhibitor in acute coronary syndromes without ST-segment elevation : the NUT-2 pilot study [J]. Circulation,2002,106(2) : 191-195.
9Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammation drugs for osteoarthritis and rheumatoid arthritis;the CLASS study : a randomized controlled trial [J] .JAMA,2000,284(6) : 1247-1255.
10White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, verse ibuprofen or diclofenac [J]. Am J Cardiol, 2002, 89(4) :425-430.
